Skip to content
10-Q

Quarterly Report

BENITEC BIOPHARMA INC. BNTC

0001193125-26-047737

← back to feed
Filed
Feb 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Feb 6, 2026 34.35M sh
Shares Diluted Q2 2026 · Dec 31, 2025 45.97M sh
Shares Diluted Q2 2026 · Dec 31, 2025 43.75M sh
Shares Diluted restated Q2 2026 · Dec 31, 2024 37.25M sh
Shares Diluted restated Q2 2026 · Dec 31, 2024 32.57M sh
Capex Q2 2026 · Dec 31, 2025 $11K
Capex Q2 2026 · Dec 31, 2024 $12K
Operating Cash Flow Q2 2026 · Dec 31, 2025 −$7.13M
Operating Cash Flow Q2 2026 · Dec 31, 2024 −$12.29M
Cash And Equivalents Q2 2026 · Dec 31, 2025 $188.79M
Cash And Equivalents Q2 2026 · Jun 30, 2025 $97.74M
Stockholders Equity Q2 2026 · Dec 31, 2025 $187.36M
Stockholders Equity Q2 2026 · Sep 30, 2025 $93.6M
Stockholders Equity Q2 2026 · Jun 30, 2025 $97.3M
Stockholders Equity Q2 2026 · Dec 31, 2024 $75.94M
Stockholders Equity Q2 2026 · Sep 30, 2024 $64.18M
Stockholders Equity Q2 2026 · Jun 30, 2024 $47.25M
Current Liabilities Q2 2026 · Dec 31, 2025 $2.8M
Current Liabilities Q2 2026 · Jun 30, 2025 $1.8M
Total Liabilities Q2 2026 · Dec 31, 2025 $3.32M
Total Liabilities Q2 2026 · Jun 30, 2025 $2.3M
Current Assets Q2 2026 · Dec 31, 2025 $189.6M
Current Assets Q2 2026 · Jun 30, 2025 $98.52M
Total Assets Q2 2026 · Dec 31, 2025 $190.68M
Total Assets Q2 2026 · Jun 30, 2025 $99.59M
Eps Diluted Q2 2026 · Dec 31, 2025 −$0.26
Eps Diluted Q2 2026 · Dec 31, 2025 −$0.48
Eps Diluted restated Q2 2026 · Dec 31, 2024 −$0.26
Eps Diluted restated Q2 2026 · Dec 31, 2024 −$0.45
Eps Basic Q2 2026 · Dec 31, 2025 −$0.26
Eps Basic Q2 2026 · Dec 31, 2025 −$0.48
Eps Basic restated Q2 2026 · Dec 31, 2024 −$0.26
Eps Basic restated Q2 2026 · Dec 31, 2024 −$0.45
Sga Expense Q2 2026 · Dec 31, 2025 $7.54M
Sga Expense Q2 2026 · Dec 31, 2025 $13.98M
Sga Expense restated Q2 2026 · Dec 31, 2024 $5.42M
Sga Expense restated Q2 2026 · Dec 31, 2024 $7.63M
Rd Expense Q2 2026 · Dec 31, 2025 $5.83M
Rd Expense Q2 2026 · Dec 31, 2025 $9.2M
Rd Expense restated Q2 2026 · Dec 31, 2024 $5.39M
Rd Expense restated Q2 2026 · Dec 31, 2024 $8.97M
Net Income Q2 2026 · Dec 31, 2025 −$11.84M
Net Income Q2 2026 · Dec 31, 2025 −$20.8M
Net Income Q2 2026 · Sep 30, 2025 −$8.97M
Net Income restated Q2 2026 · Dec 31, 2024 −$9.55M
Net Income restated Q2 2026 · Dec 31, 2024 −$14.61M
Net Income Q2 2026 · Sep 30, 2024 −$5.06M
Operating Income Q2 2026 · Dec 31, 2025 −$13.38M
Operating Income Q2 2026 · Dec 31, 2025 −$23.18M
Operating Income restated Q2 2026 · Dec 31, 2024 −$10.81M
Operating Income restated Q2 2026 · Dec 31, 2024 −$16.6M
Revenue Q2 2026 · Dec 31, 2025 $0
Revenue Q2 2026 · Dec 31, 2025 $0
Revenue Q2 2026 · Dec 31, 2024 $0
Revenue Q2 2026 · Dec 31, 2024 $0